Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 269M | 99M | 88M | 75M | 54M |
| Gross Profit | 127M | 51M | 44M | 31M | 20M |
| Operating Income | 10M | 14M | 11M | -7M | -20M |
| EBITDA | 12M | 18M | 15M | -10M | -15M |
| Net Income | -68M | -28M | -26M | -42M | -34M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$11.10
-1.29% today
1Y Change
-2.77%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vireo Growth Inc. (VREOF) is a Healthcare stock with a market cap of $430.00M and listed on OTC. The stock last traded around $11.10 and down 2.8% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +170.4%, EPS growth of +41.1%, a dividend yield of 0.0%. What stands out right now is revenue +170.4%, EPS +41.1%, free cash flow -19.0% with operating margin 1.6% and ROIC 0.6%. Valuation is more restrained than many high-expectation growth names at price/sales 1.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VREOF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VREOF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VREOF Max Drawdown
-53.12%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VREOF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$54.4M
-27.0% YoY
FY Net Income
-$33.7M
+20.6% YoY
Free Cash Flow
-$48.6M
-105.5% YoY
Revenue Growth
+170.4%
EPS Growth
+41.1%
Gross Margin
47.3%
Net Margin
-25.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 269M | 99M | 88M | 75M | 54M |
| Gross Profit | 127M | 51M | 44M | 31M | 20M |
| Operating Income | 10M | 14M | 11M | -7M | -20M |
| EBITDA | 12M | 18M | 15M | -10M | -15M |
| Net Income | -68M | -28M | -26M | -42M | -34M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 102M | 92M | 16M | 15M | 15M |
| Total Assets | 817M | 279M | 183M | 159M | 167M |
| Total Liabilities | 510M | 223M | 199M | 156M | 124M |
| Shareholder Equity | 307M | 56M | -16M | 3M | 43M |
| Total Debt | 304M | 90M | 81M | 139M | 109M |
| Net Debt | 201M | -2M | 65M | 124M | 94M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
31M
-68.9% YoY
Capital Expenditures
18M
-224.4% YoY
Free Cash Flow
49M
-105.5% YoY
Key ratios
Gross Margin
47.3%
Operating Margin
1.6%
Net Margin
-25.3%
ROE
-31.2%
Debt / Equity
0.99x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.